RESUMEN
Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.
RESUMEN
Objective The present study compares immune and endocrine parameters between HIV-infected patients who underwent the Immune Reconstitution Inflammatory Syndrome (IRIS-P) during antiretroviral therapy (ART) and HIV-patients who did not undergo the syndrome (non-IRIS-P). Materials and methods Blood samples were obtained from 31 HIV-infected patients (15 IRIS-P and 16 non-IRIS-P) before ART (BT) and 48 ± 2 weeks after treatment initiation (AT). Plasma Interleukin-6 (IL-6) and Interleukin-18 (IL-18) were determined by ELISA. Cortisol, dehydroepiandrosterone sulfate (DHEA-S) and thyroxin concentrations were measured using chemiluminescence immune methods. Results Concentrations of IL-6 (7.9 ± 1.9 pg/mL) and IL-18 (951.5 ± 233.0 pg/mL) were significantly higher (p < 0.05) in IRIS-P than in non-IRIS-P (3.9 ± 1.0 pg/mL and 461.0 ± 84.4 pg/mL, respectively) BT. Mean T4 plasma level significantly decreased in both groups of patients after treatment (p < 0.05). In both groups cortisol levels were similar before and after ART (p > 0.05). Levels of DHEA-S in IRIS-P decreased AT (1080.5 ± 124.2 vs. 782.5 ± 123.8 ng/mL, p < 0.05) and they were significantly lower than in non-IRIS-P (782.5 ± 123.8 vs. 1203.7 ± 144.0 ng/mL, p < 0.05). IRIS-P showed higher values of IL-6 and IL-18 BT and lower levels of DHEA-S AT than in non-IRIS-P. Conclusion These parameters could contribute to differentiate IRIS-P from non-IRIS-P. The significant decrease in DHEA-S levels in IRIS-P after ART might suggest a different adrenal response in these patients, which may reflect the severity of the disease.
Asunto(s)
Terapia Antirretroviral Altamente Activa/efectos adversos , Biomarcadores/sangre , Infecciones por VIH/sangre , Síndrome Inflamatorio de Reconstitución Inmune/sangre , Relación CD4-CD8 , Sulfato de Deshidroepiandrosterona/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Infecciones por VIH/metabolismo , Humanos , Hidrocortisona/sangre , Síndrome Inflamatorio de Reconstitución Inmune/inmunología , Síndrome Inflamatorio de Reconstitución Inmune/metabolismo , Interleucina-18/sangre , Interleucina-6/sangre , Luminiscencia , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Tiroxina/sangre , Carga ViralRESUMEN
ABSTRACT Objective The present study compares immune and endocrine parameters between HIV-infected patients who underwent the Immune Reconstitution Inflammatory Syndrome (IRIS-P) during antiretroviral therapy (ART) and HIV-patients who did not undergo the syndrome (non-IRIS-P). Materials and methods Blood samples were obtained from 31 HIV-infected patients (15 IRIS-P and 16 non-IRIS-P) before ART (BT) and 48 ± 2 weeks after treatment initiation (AT). Plasma Interleukin-6 (IL-6) and Interleukin-18 (IL-18) were determined by ELISA. Cortisol, dehydroepiandrosterone sulfate (DHEA-S) and thyroxin concentrations were measured using chemiluminescence immune methods. Results Concentrations of IL-6 (7.9 ± 1.9 pg/mL) and IL-18 (951.5 ± 233.0 pg/mL) were significantly higher (p < 0.05) in IRIS-P than in non-IRIS-P (3.9 ± 1.0 pg/mL and 461.0 ± 84.4 pg/mL, respectively) BT. Mean T4 plasma level significantly decreased in both groups of patients after treatment (p < 0.05). In both groups cortisol levels were similar before and after ART (p > 0.05). Levels of DHEA-S in IRIS-P decreased AT (1080.5 ± 124.2 vs. 782.5 ± 123.8 ng/mL, p < 0.05) and they were significantly lower than in non-IRIS-P (782.5 ± 123.8 vs. 1203.7 ± 144.0 ng/mL, p < 0.05). IRIS-P showed higher values of IL-6 and IL-18 BT and lower levels of DHEA-S AT than in non-IRIS-P. Conclusion These parameters could contribute to differentiate IRIS-P from non-IRIS-P. The significant decrease in DHEA-S levels in IRIS-P after ART might suggest a different adrenal response in these patients, which may reflect the severity of the disease.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Biomarcadores/sangre , Infecciones por VIH/sangre , Terapia Antirretroviral Altamente Activa/efectos adversos , Síndrome Inflamatorio de Reconstitución Inmune/sangre , Tiroxina/sangre , Ensayo de Inmunoadsorción Enzimática , Hidrocortisona/sangre , Infecciones por VIH/inmunología , Infecciones por VIH/metabolismo , Infecciones por VIH/tratamiento farmacológico , Estudios Prospectivos , Interleucina-6/sangre , Relación CD4-CD8 , Sulfato de Deshidroepiandrosterona/sangre , Carga Viral , Interleucina-18/sangre , Luminiscencia , Síndrome Inflamatorio de Reconstitución Inmune/inmunología , Síndrome Inflamatorio de Reconstitución Inmune/metabolismoRESUMEN
BACKGROUND: The biological relevance of nuclear ErbB-2/HER2 (NuclErbB-2) presence in breast tumors remains unexplored. In this study we assessed the clinical significance of ErbB-2 nuclear localization in primary invasive breast cancer. The reporting recommendations for tumor marker prognostic studies (REMARK) guidelines were used as reference. METHODS: Tissue microarrays from a cohort of 273 primary invasive breast carcinomas from women living in Chile, a Latin American country, were examined for membrane (MembErbB-2) and NuclErbB-2 expression by an immunofluorescence (IF) protocol we developed. ErbB-2 expression was also evaluated by immunohistochemistry (IHC) with a series of antibodies. Correlation between NuclErbB-2 and MembErbB-2, and between NuclErbB-2 and clinicopathological characteristics of tumors was studied. The prognostic value of NuclErbB-2 in overall survival (OS) was evaluated using Kaplan-Meier method, and Cox model was used to explore NuclErbB-2 as independent prognostic factor for OS. RESULTS: The IF protocol we developed showed significantly higher sensitivity for detection of NuclErbB-2 than IHC procedures, while its specificity and sensitivity to detect MembErbB-2 were comparable to those of IHC procedures. We found 33.6% NuclErbB-2 positivity, 14.2% MembErbB-2 overexpression by IF, and 13.0% MembErbB-2 prevalence by IHC in our cohort. We identified NuclErbB-2 positivity as a significant independent predictor of worse OS in patients with MembErbB-2 overexpression. NuclErbB-2 was also a biomarker of lower OS in tumors that overexpress MembErbB-2 and lack steroid hormone receptors. CONCLUSIONS: We revealed a novel role for NuclErbB-2 as an independent prognostic factor of poor clinical outcome in MembErbB-2-positive breast tumors. Our work indicates that patients presenting NuclErbB-2 may need new therapeutic strategies involving specific blockage of ErbB-2 nuclear migration.
Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/metabolismo , Carcinoma/metabolismo , Proteínas Nucleares/metabolismo , Receptor ErbB-2/metabolismo , Adulto , Anciano , Biomarcadores de Tumor/análisis , Neoplasias de la Mama/química , Carcinoma/química , Chile , Estudios de Cohortes , Femenino , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Proteínas de la Membrana/análisis , Proteínas de la Membrana/metabolismo , Análisis por Micromatrices , Persona de Mediana Edad , Proteínas Nucleares/análisis , Pronóstico , Modelos de Riesgos Proporcionales , Receptor ErbB-2/análisisRESUMEN
Introducción: Por medio de la realización del testeo de la sobreexpresión y/o amplificación de HER2 los médicos pueden seleccionar adecuadamente a las pacientes que se beneficiarán de la terapia anti HER2. En Argentina, antes de 2003 sólo pocos patólogos realizaban la prueba de HER2 utilizando métodos no estandarizados de inmunohistoquímica (IHQ) con resultados dudosos y no reproducibles y además existiendo algunas partes del país sin posibilidades de diagnóstico. Objetivo: Generar un Programa Nacional de Detección de la sobreexpresión de HER2 que permita el acceso al diagnóstico en todo el país, mediante una técnica estandarizada y validada. Integrar un equipo de patólogos entrenados en IHC, que pudieran satisfacer las demandas realizando en forma rápida y fidedigna la detección de la sobreexpresión de HER2. Materiales y método: En agosto de 2003 se formó una red de trece patólogos; dentro del grupo se designó un coordinador, responsable del entrenamiento y la evaluación de los centros participantes, y dos consultores técnicos a cargo del control de calidad (interno y externo) y la estandarización de la técnica. Desde febrero de 2004 hasta diciembre de 2010 se realizaron las determinaciones de la sobreexpresión de HER2 mediante la técnica de IHC, con un anticuerpo policlonal anti HER2 (Dako), recuperación antigénica en microondas, sistema de detección EnVision (Dako) y revelado con diaminobenzidina. Para interpretar los resultados se usó el score de 0 a 3+, considerándose positivos tumores que muestren intensidad moderada (2+) o intensa (3+) en toda la membrana celular, en más del 30% de las células evaluadas. Resultados: Se realizaron 34.640 casos (Figura 5). Conclusiones: La formación del Programa Nacional de HER2 permitió el acceso al test de HER2 en todo el país con una técnica estandarizada y reproducible en todos los centros participantes. La prevalencia de HER2 en nuestra muestra fue del 13,2% (4.573) y similar a las publicadas en otras poblaciones.
Asunto(s)
Neoplasias de la Mama , InmunohistoquímicaRESUMEN
C57BL/6 mice infected with Trypanosoma cruzi, the causal agent of Chagas' disease, develop severe thymocyte depletion paralleled by an inflammatory syndrome mediated by tumor necrosis factor-alpha (TNF-alpha). The exacerbated inflammatory reaction induces the activation of hypothalamus-pituitary-adrenal (HPA) axis with the consequent release of corticosterone (CT) into the circulation as a protective response. Thymocyte apoptosis has been related to a rise in TNF-alpha and CT levels, and both mediators are increased in T. cruzi-infected C57BL/6 mice. The depletion of immature CD4(+)CD8(+) thymocytes by apoptosis following infection with the parasite was still present in mice defective in both types of TNF-receptors (double knockout). However, thymic atrophy was prevented by adrenalectomy combined with RU486 administration, demonstrating that this is a CT-driven phenomenon. Our results put emphasis on the importance of an appropriated immuno-endocrine balance during T. cruzi infection and show that functional deviations in the immuno-endocrine equilibrium have profound effects on the thymus and disease outcome.
Asunto(s)
Enfermedad de Chagas/inmunología , Neuroinmunomodulación/inmunología , Timo/inmunología , Timo/parasitología , Trypanosoma cruzi/inmunología , Enfermedad Aguda , Animales , Apoptosis/inmunología , Atrofia , Relación CD4-CD8 , Enfermedad de Chagas/mortalidad , Enfermedad de Chagas/patología , Corticosterona/sangre , Corticosterona/inmunología , Antagonistas de Hormonas/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mifepristona/farmacología , Sistemas Neurosecretores/inmunología , Sistemas Neurosecretores/parasitología , Receptores de Glucocorticoides/antagonistas & inhibidores , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Timo/patología , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/inmunologíaRESUMEN
BACKGROUND & AIMS: Postprandial increases in portal pressure may influence esophageal variceal rupture. The effects of chronic propranolol and octreotide (100 and 200 microg subcutaneously in a single dose) on postprandial hemodynamics were evaluated. METHODS: FIRST STUDY: 36 cirrhotic patients were studied at baseline and 30 and 60 minutes after a standard meal and then treated with propranolol (139 +/- 9 mg/d during 39 +/- 2 days). SECOND STUDY: After baseline measurements, patients were randomized into 3 groups: (1) placebo, (2) octreotide (100 microg), or (3) octreotide (200 microg) (n = 12 for each group). Thirty minutes postinjection a new baseline was established and measurements were repeated 30 and 60 minutes after the meal. RESULTS: First study: Baseline portal pressure was 18.1 +/- 1.2 mm Hg, 30 and 60 minutes after the meal it was 21.5 +/- 0.8 mm Hg and 20.5 +/- 0.8 mm Hg, respectively (both P < 0.01 vs. baseline). Cardiac index (CI) was 4.5 +/- 0.2, 4.8 +/- 0.2, and 4.9 +/- 0.2 L x min(-1) x m(-2), respectively (both P < 0.05 vs. baseline). Peripheral vascular resistance was 1012 +/- 56, 902 +/- 51 (P = NS), and 884 +/- 49 dynes x sec x cm(-5) (P< 0.05 vs. baseline), respectively. Second study: Propranolol and placebo did not blunt postprandial increase in portal pressure. Octreotide (100 microg) partially ameliorated postprandial increase in portal pressure. Octreotide (200 microg) significantly enhanced the portal hypotensive effect of propranolol and blunted the postprandial increase in portal pressure. CONCLUSIONS: Octreotide blunts postprandial increase in portal pressure not prevented by long-term propranolol administration.
Asunto(s)
Antagonistas Adrenérgicos beta/administración & dosificación , Circulación Hepática/efectos de los fármacos , Cirrosis Hepática/tratamiento farmacológico , Octreótido/administración & dosificación , Propranolol/administración & dosificación , Vasoconstrictores/administración & dosificación , Cateterismo , Quimioterapia Combinada , Femenino , Venas Hepáticas , Humanos , Masculino , Persona de Mediana Edad , Presión Portal/efectos de los fármacos , Periodo PosprandialRESUMEN
Se presenta la asociación de xantelasma y SLO y se la vincula al desarollo de AE. Paciente de cuarenta y cuatro años con xantelasma, SLO y dislipidemia. Se investigan otros factores de riesgo: tabaquismo - fumador de más de 30 cigarillos por día - e hipertensión arterial. Los estudios clínicos y cardiológicos revelan ECG en reposo normal, ergometría positiva y auscultación soplo femoral izquierdo. Por métodos no invasivos se informa una obstrucción parcial aterosclerosa de la ilíaca izquierda. Son necesarios nuevos casos para determinar con exactitud el significado de la asociación xantelasma-SLO